Sunandana Chandra

7.1k total citations · 1 hit paper
49 papers, 1.2k citations indexed

About

Sunandana Chandra is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Sunandana Chandra has authored 49 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 15 papers in Molecular Biology and 13 papers in Immunology. Recurrent topics in Sunandana Chandra's work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (11 papers). Sunandana Chandra is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (16 papers) and Immunotherapy and Immune Responses (11 papers). Sunandana Chandra collaborates with scholars based in United States, Italy and France. Sunandana Chandra's co-authors include Jeffrey A. Sosman, Douglas B. Johnson, Francis J. Giles, Wade T. Iams, Young Kwang Chae, Jaehyuk Choi, Marcelo Cruz, Ayush Arya, Elizabeth J. Davis and Benedito A. Carneiro and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sunandana Chandra

46 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

2018 321 citations Young Kwang Chae, Ayush Arya et al. Journal for ImmunoTherapy of Cancer profile →

Peers

Sunandana Chandra

ONCOL

IMMUN

PRM

EPIDE

Lucia Festino Italy

Luigia Stefania Stucci Italy

Vito Vanella Italy

Jieqing Chen China

Shu‐Fen Chiang Taiwan

Enrica T. Tanda Italy

Elizabeth Liniker Australia

Yan-Gao Man United States

Geraldine O’Sullivan Coyne United States

Lucia Festino Italy

Sunandana Chandra

880 ×1.1

ONCOL

368 ×0.9

375 ×1.1

IMMUN

190 ×0.9

PRM

69 ×0.5

EPIDE

Citations per year, relative to Sunandana Chandra Sunandana Chandra (= 1×) peers Lucia Festino

Countries citing papers authored by Sunandana Chandra

Since Specialization

Citations

This map shows the geographic impact of Sunandana Chandra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunandana Chandra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunandana Chandra more than expected).

Fields of papers citing papers by Sunandana Chandra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunandana Chandra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunandana Chandra. The network helps show where Sunandana Chandra may publish in the future.

Co-authorship network of co-authors of Sunandana Chandra

This figure shows the co-authorship network connecting the top 25 collaborators of Sunandana Chandra. A scholar is included among the top collaborators of Sunandana Chandra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunandana Chandra. Sunandana Chandra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miller, David M., Vernon K. Sondak, Sunandana Chandra, et al.. (2025). Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain. 3(1).

Piha‐Paul, Sarina A., Macarena I. de la Fuente, Fábio M. Iwamoto, et al.. (2024). Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3107–3107. 3 indexed citations

Rapisuwon, Suthee, Richard D. Carvajal, George Ansstas, et al.. (2024). Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309).. Journal of Clinical Oncology. 42(16_suppl). 9509–9509. 2 indexed citations

Zakharia, Yousef, Sylvia Lee, Robert M. Jotte, et al.. (2024). Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival.. Journal of Clinical Oncology. 42(16_suppl). 2617–2617. 1 indexed citations

Patel, Sapna P., Megan Othus, Paul Wright, et al.. (2023). LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801. Annals of Oncology. 34. S1288–S1288. 7 indexed citations

Sosman, Jeffrey A., et al.. (2023). Endocrine side effects of immune checkpoint inhibitors. Frontiers in Endocrinology. 14. 1157805–1157805. 25 indexed citations

Lukas, Rimas V., Jigisha P. Thakkar, Massimo Cristofanilli, et al.. (2022). Leptomeningeal metastases: the future is now. Journal of Neuro-Oncology. 156(3). 443–452. 16 indexed citations

Ribas, Antoni, Alain P. Algazi, Paolo A. Ascierto, et al.. (2021). Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications. 12(1). 5022–5022. 1 indexed citations

Ribas, Antoni, Alain P. Algazi, Paolo A. Ascierto, et al.. (2020). PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nature Communications. 11(1). 60 indexed citations

10.

Rapisuwon, Suthee, Sapna P. Patel, Richard D. Carvajal, et al.. (2019). Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.. Journal of Clinical Oncology. 37(15_suppl). TPS9604–TPS9604. 2 indexed citations

11.

Kibbi, Nour, Brandon Worley, Joshua L. Owen, et al.. (2019). Sebaceous carcinoma: controversies and their evidence for clinical practice. Archives of Dermatological Research. 312(1). 25–31. 16 indexed citations

12.

Fenton, Sarah E., Jeffrey A. Sosman, & Sunandana Chandra. (2019). Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. Cancer Drug Resistance. 2(3). 744–761. 15 indexed citations

13.

Davis, Elizabeth J., Douglas B. Johnson, Jeffrey A. Sosman, & Sunandana Chandra. (2018). Melanoma: What do all the mutations mean?. Cancer. 124(17). 3490–3499. 121 indexed citations

14.

Smith, Melanie, et al.. (2018). Pseudoprogression of Melanoma Brain Metastases. Current Oncology Reports. 20(11). 91–91. 15 indexed citations

15.

Cavalcante, Ludimila, Akansha Chowdhary, Jeffrey A. Sosman, & Sunandana Chandra. (2018). Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. American Journal of Clinical Dermatology. 19(5). 657–670. 16 indexed citations

16.

Chae, Young Kwang, Ayush Arya, Wade T. Iams, et al.. (2018). Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). Journal for ImmunoTherapy of Cancer. 6(1). 39–39. 321 indexed citations breakdown →

17.

Iams, Wade T., Jeffrey A. Sosman, & Sunandana Chandra. (2017). Novel Targeted Therapies for Metastatic Melanoma. The Cancer Journal. 23(1). 54–58. 16 indexed citations

18.

Minami, Christina A., Jeffrey D. Wayne, Anthony D. Yang, et al.. (2016). National Evaluation of Hospital Performance on the New Commission on Cancer Melanoma Quality Measures. Annals of Surgical Oncology. 23(11). 3548–3557. 12 indexed citations

19.

Weiss, Sarah A., Sunandana Chandra, & Anna C. Pavlick. (2014). Update on Vaccines for High-Risk Melanoma. Current Treatment Options in Oncology. 15(2). 269–280. 5 indexed citations

20.

Chandra, Sunandana & Anna C. Pavlick. (2012). Targeted Therapies for Metastatic Melanoma. Dermatologic Clinics. 30(3). 517–524. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact